Welcome to LookChem.com Sign In|Join Free

CAS

  • or

220460-92-4

Post Buying Request

220460-92-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

220460-92-4 Usage

General Description

The chemical 10-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine is a benzodiazepine derivative that contains a pyrrolo[2,1-c][1,4]benzodiazepine backbone with a 2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl substituent. 10-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine is a potential drug candidate for the treatment of various neurological and psychiatric disorders, as well as cancer. It has been studied for its potential anxiolytic, antidepressant, and antitumor activities. The chemical structure of this compound allows it to interact with specific receptors in the central nervous system, which can potentially modulate neurotransmitter activity and provide therapeutic effects. Further research is necessary to fully understand the pharmacological properties and potential applications of this compound.

Check Digit Verification of cas no

The CAS Registry Mumber 220460-92-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,0,4,6 and 0 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 220460-92:
(8*2)+(7*2)+(6*0)+(5*4)+(4*6)+(3*0)+(2*9)+(1*2)=94
94 % 10 = 4
So 220460-92-4 is a valid CAS Registry Number.

220460-92-4Relevant articles and documents

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Frantz, Marie-Céline,Pellissier, Lucie P.,Pflimlin, Elsa,Loison, Stéphanie,Gandiá, Jorge,Marsol, Claire,Durroux, Thierry,Mouillac, Bernard,Becker, Jér?me A. J.,Le Merrer, Julie,Valencia, Christel,Villa, Pascal,Bonnet, Dominique,Hibert, Marcel

, p. 8670 - 8692 (2018/10/05)

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.

TRICYCLIC VASOPRESSIN AGONISTS

-

Page 33-34, (2010/02/08)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 220460-92-4